Curis | CRIS - Operating Expenses


Curis reported $11.52M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Alaunos Therapeutics USD 952K 60K Jun/2026
Amgen USD 5.69B 6B Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
Bayer EUR 9.92B 121M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
CSL USD 5.7B 2.82B Dec/2025
Curis USD 11.52M 2.5M Mar/2026
Eli Lilly USD 10.52B 496M Jun/2026
Exelixis USD 390.27M 10M Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Novartis USD 9.88B 325M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 10.51B 598M Sep/2026
Takeda JPY 981.78B 36.71B Sep/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026
Verastem USD 63.57M 4.56M Mar/2026